The Vossel lab investigates Alzheimer’s disease (AD) and related dementias in transgenic mouse models of AD as well as human clinical trials. We are studying mechanisms and novel therapies for epileptic activity in AD. The goal of the laboratory investigation to discover therapies that target novel aspects of the tau protein in the biology of AD. We are studying cell-signaling functions of tau that are distinct from its traditional role as a microtubule-binding protein (Science and JCB). Clinical investigation focuses on silent seizures in AD and includes a phase 2a trial of an antiseizure drug to treat AD-associated network hyperexcitability. Studies include overnight electroencephalographic recordings, polysomnography, and magnetoencephalography. More information about the trial can be found on ClinicalTrials.gov.
We have shown that patients with Alzheimer’s disease have seizures and network hyperactivity at rates that are much higher than previous estimates, because they are usually non-motor or silent in nature. Seizures are important to recognize in patients with Alzheimer’s disease because they can lead to a more rapid cognitive decline (Lancet Neurology and Annals of Neurology).
Keith Vossel Associate Professor, Principal Investigator, Director of Memory Clinic
Samuel Peters Lab Manager, Researcher
Kasey Ah Pook Clinical Research Coordinator
Madelyn Castro Clinical Research Coordinator
Jessica Choquette Researcher
Stephen Martin Undergraduate Researcher
Allyssa Phillips Postdoctoral Associate
Nisha Venkateswaran Researcher